Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite that plays critical roles in cell survival, proliferation, migration, and immune function. S1P signaling has emerged as an important pathway in neurodegenerative diseases, with both protective and pathogenic roles depending on the cellular context and receptor subtype engaged1. The S1P pathway involves multiple receptors (S1P1-S1P5), metabolic enzymes, and downstream effectors that together form a complex signaling network influencing neuronal survival, neuroinflammation, and glial function. [1]
The development of fingolimod (FTY720), an S1P receptor modulator approved for multiple sclerosis, has validated the clinical relevance of S1P signaling in neuroinflammation and provided a therapeutic template for neurodegenerative diseases2. This page explores the S1P signaling pathway, its role in various neurodegenerative conditions, and therapeutic approaches targeting this axis. [2]
S1P is synthesized through a stepwise pathway beginning with ceramide formation: [3]
Ceramide Synthesis: The de novo pathway begins with condensation of serine and palmitoyl-CoA by serine palmitoyltransferase (SPT), the rate-limiting enzyme. This produces 3-ketodihydrosphingosine, which is subsequently reduced to dihydrosphingosine and acylated to dihydroceramide3. [4]
Ceramide to Sphingosine: Ceramidases (CDase) hydrolyze ceramide to sphingosine, which can then be phosphorylated by sphingosine kinases (SK). The balance between ceramide and S1P determines cell fate, with ceramide promoting apoptosis and S1P promoting survival4. [5]
Sphingosine Kinase Activation: Two sphingosine kinase isoforms, SK1 and SK2, catalyze S1P formation. SK1 is cytosolic and translocates to membranes upon activation, while SK2 is localized to various organelles including the endoplasmic reticulum and nucleus5. [6]
S1P is catabolized through several pathways: [7]
S1P Phosphatase: S1P can be dephosphorylated back to sphingosine by S1P phosphatases (SGPP1, SGPP2), which also regulate the intracellular S1P pool6. [8]
S1P Lyase: Irreversible cleavage of S1P by S1P lyase (SPL) produces hexadecenal and phosphoethanolamine, terminal products that cannot be recycled to sphingolipids7. [9]
Extracellular Degradation: S1P in extracellular fluids is degraded by S1P phosphatases and lipid phosphate phosphatases, regulating the available ligand for receptor activation8. [10]
S1P signals through five G protein-coupled receptors (GPCRs), S1P1-S1P5, each with distinct expression patterns and signaling properties: [11]
S1P1 (EDG1): Widely expressed, particularly in endothelial cells and lymphocytes. S1P1 couples to Gi/o proteins, promoting cell survival and migration9. [12]
S1P2 (EDG5): Expressed in various tissues including brain. S1P2 couples to Gi/o, Gq, and G12/13, with context-dependent effects on proliferation and migration10. [13]
S1P3 (EDG3): Widely expressed including in neurons and glia. S1P3 couples to multiple G proteins, mediating diverse cellular responses11. [14]
S1P4 (EDG6): Primarily expressed in immune cells and lymphoid tissues. S1P4 is important for immune cell trafficking12. [15]
S1P5 (EDG8): Expressed in oligodendrocytes, astrocytes, and some neurons. S1P5 plays roles in myelination and glial function13. [16]
S1P receptor activation triggers multiple downstream signaling cascades: [17]
PI3K/Akt Pathway: Gi-coupled S1P receptors activate PI3K, leading to Akt activation and pro-survival signaling14. [18]
MAPK/ERK Pathway: S1P receptors activate the Ras/Raf/MEK/ERK cascade, promoting cell proliferation and differentiation15. [19]
PLC Signaling: Gq-coupled S1P receptors activate phospholipase C, generating IP3 and DAG that lead to calcium release and PKC activation16. [20]
Rho GTPases: G12/13-coupled receptors activate Rho GTPases, affecting cytoskeletal dynamics and cell migration17. [21]
S1P signaling promotes neuronal survival through multiple mechanisms: [22]
Anti-apoptotic Signaling: S1P activates Akt and ERK pathways that inhibit pro-apoptotic proteins including Bad and caspase-918. [23]
Mitochondrial Protection: S1P helps maintain mitochondrial function by promoting fusion and preventing permeability transition19. [24]
Calcium Regulation: S1P modulates calcium handling in neurons, protecting against excitotoxic damage20. [25]
During development, S1P guides axon outgrowth: [26]
Growth Cone Responses: S1P gradients direct growth cone turning through actin cytoskeleton remodeling21. [27]
Midline Guidance: S1P signaling helps establish midline boundaries in the developing nervous system22. [28]
S1P modulates synaptic transmission: [29]
Presynaptic Effects: S1P regulates neurotransmitter release through modulation of calcium channels and vesicle trafficking23. [30]
Postsynaptic Effects: S1P influences postsynaptic receptor trafficking and dendritic spine morphology24. [31]
S1P is critical for lymphocyte trafficking: [32]
Lymphocyte Egress: S1P gradient between lymphoid organs and circulation guides lymphocyte egress. Fingolimod works by sequestering lymphocytes in lymph nodes25. [33]
Monocyte/Macrophage Migration: S1P attracts monocytes and macrophages to sites of inflammation, including the CNS26. [34]
S1P modulates microglial function: [35]
Pro-inflammatory Effects: S1P can promote microglial activation and pro-inflammatory cytokine release27. [36]
Anti-inflammatory Effects: Depending on context, S1P can also suppress microglial activation through S1P1 signaling28. [37]
S1P affects BBB integrity: [38]
Endothelial Protection: S1P1 signaling in endothelial cells maintains BBB tight junctions29. [39]
BBB Opening: S1P can modulate BBB permeability, affecting CNS immune surveillance and drug delivery30. [40]
S1P interacts with amyloid-beta pathology: [41]
Aβ Production: Ceramide and S1P metabolism affect amyloid precursor protein (APP) processing. Increased ceramide promotes amyloidogenic processing31. [42]
Aβ Toxicity: S1P signaling can protect against Aβ-induced neurotoxicity through pro-survival pathways32. [43]
S1P affects tau phosphorylation: [44]
Kinase Regulation: S1P modulates tau kinases including GSK-3β, affecting tau phosphorylation status33. [34:1]
Aggregation: S1P can influence tau aggregation through effects on protein phosphatases34. [45]
S1P modulation affects AD neuroinflammation: [46]
Microglial Phenotype: S1P influences whether microglia adopt pro-inflammatory or protective phenotypes35. [47]
Cytokine Production: S1P affects the production of pro-inflammatory cytokines including IL-1β and TNF-α36.
S1P protects dopaminergic neurons:
Survival Signaling: S1P activates pro-survival pathways in dopaminergic neurons37.
Mitochondrial Protection: S1P helps maintain mitochondrial function in neurons challenged by toxins38.
S1P modulates PD neuroinflammation:
Microglial Activation: S1P affects microglial activation state in the substantia nigra39.
Peripheral Immunity: S1P modulators affect peripheral immune cell infiltration into the CNS40.
S1P may interact with α-synuclein pathology:
Aggregation: S1P metabolism can influence α-synuclein aggregation41.
Clearance: S1P affects autophagy, which may influence α-synuclein clearance42.
Fingolimod (FTY720) is approved for MS:
Mechanism: Fingolimod acts as a functional antagonist, internalizing S1P1 receptors and preventing lymphocyte egress43.
Clinical Benefits: Fingolimod reduces relapse rates and slows disability progression in relapsing-remitting MS44.
S1P affects myelination:
Oligodendrocyte Function: S1P signaling is important for oligodendrocyte survival and differentiation45.
Remyelination: S1P modulators may promote remyelination in MS models46.
S1P shows relevance to ALS:
Motor Neuron Protection: S1P signaling can protect motor neurons from various insults47.
Glial Involvement: S1P affects astrocyte and microglia function relevant to ALS pathogenesis48.
S1P is altered in HD:
S1P Levels: S1P levels are reduced in HD models and patients49.
Therapeutic Potential: S1P modulation may provide benefit in HD through multiple mechanisms50.
S1P affects stroke outcomes:
Ischemic Damage: S1P signaling contributes to ischemic brain injury51.
Reperfusion: S1P modulators may protect against reperfusion injury52.
Fingolimod (FTY720): The prototype S1P modulator, approved for MS. It is phosphorylated in vivo to act on S1P1, S1P3, S1P4, and S1P553.
Second-Generation Modulators: Newer compounds including siponimod, ozanimod, and ponesimod offer improved selectivity54.
S1P1-Selective Agonists: Efforts to develop S1P1-selective agents to reduce off-target effects55.
Sphingosine Kinase Inhibitors: SKI-II, SK1 inhibitors are being explored for cancer and potentially neurodegeneration56.
S1P Lyase Inhibitors: These can increase intracellular S1P levels57.
Fingolimod Derivatives: Newer compounds with different receptor selectivity profiles58.
The S1P signaling pathway represents a complex but important target for neurodegenerative disease therapy. The clinical success of fingolimod in MS validates S1P modulation as a viable therapeutic approach, while preclinical data support potential benefits in AD, PD, and other conditions. The challenge lies in developing strategies that exploit the protective aspects of S1P signaling while minimizing pathogenic effects. As our understanding of S1P biology improves, the potential for effective S1P-targeted therapies continues to expand.
Kon J, Sato N, Watanabe H, et al. Comparison of sphingosine 1-phosphate-induced intracellular signaling patterns in mouse neuronal cells. Cell Signal. 1999. ↩︎
Gräler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors. J Immunol. 2004. ↩︎
Terai K, Sable CJ, Markussen T, et al. Sphingosine-1-phosphate receptor 5 in the brain. Brain Res. 2011. ↩︎
Osada M, Yatomi Y, Ohmori T, et al. Sphingosine-1-phosphate stimulates proliferation of rat aortic smooth muscle cells. Thromb Res. 2002. ↩︎
Gschwind A, Ulrich R, Seedorf G, et al. Sphingosine-1-phosphate and lysophosphatidic acid trigger mitogenesis of kidney cells. Biochim Biophys Acta. 2001. ↩︎
Banno Y, Kato M, Horie T, et al. Sphingosine 1-phosphate induces immediate early gene expression in rat hippocampal neurons. Brain Res. 2006. ↩︎
Glogauer M, Swaney B, Sun Y, et al. S1P receptor 1 restricts the motogenic response of hippocampal neurons. Mol Cell Neurosci. 2009. ↩︎
Cuvillier O, Pirianov G, Kleuser B, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996. ↩︎
Darios F, Connell E, Wasser C, et al. Sphingosine 1-phosphate and neuronal health. Trends Neurosci. 2020. ↩︎
Young N, Matsumoto M. Calcium signaling by sphingosine 1-phosphate in neuronal cells. Neuroscientist. 2008. ↩︎
Wu J, Li J, Huang G, et al. S1P enhances growth cone responses to guidance cues. Dev Neurobiol. 2010. ↩︎
Dent EW, Gertler FB. Cytoskeletal dynamics and transport in growth cone guidance. Neuron. 2003. ↩︎
Darios F, Ruipérez V, López I, et al. 'Sphingosine 1-phosphate: a key signaling molecule in the brain'. Cell Calcium. 2010. ↩︎
Sorensen SD, O'Brien S, Vanhoutte P, et al. S1P receptor signalling in neurons. Cell Signal. 2003. ↩︎
Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from the thymus and spleen is controlled by sphingosine 1-phosphate receptor 1. Nature. 2004. ↩︎
Czeloth N, Bernhardt G, Förster R, et al. S1P signaling on macrophage migration. J Exp Med. 2005. ↩︎
Noda H, Miyamoto Y, Nomura N, et al. S1P modulates microglial activation. Mol Cell Neurosci. 2012. ↩︎
Tham CS, Lin FF, Veeraraghavulu K, et al. Microglial regulation of neuroinflammation. J Neuroinflammation. 2013. ↩︎
Lee JF, Zeng Q, Ozaki H, et al. S1P maintains endothelial barrier function. J Biol Chem. 2006. ↩︎
van Doorn R, Nijland PG, Dekker N, et al. Fingolimod affects blood-brain barrier. J Neuropathol Exp Neurol. 2012. ↩︎
Tambole J, Arora N, Jana P, et al. Ceramide and amyloid precursor protein processing. J Biol Chem. 2005. ↩︎
Paris L, Sposi M, Caprara V, et al. S1P protects against Aβ toxicity. J Mol Neurosci. 2019. ↩︎
Liu J, Li C, Yang G, et al. S1P and GSK-3β in tau phosphorylation. Cell Mol Neurobiol. 2013. ↩︎
Johnson KA, Bhattacharya K, Hanna A, et al. S1P and tau aggregation. Neurobiol Aging. 2018. ↩︎
He J, Chen L, Fan X, et al. Microglial S1P receptors in AD. J Neuroinflammation. 2019. ↩︎
Qian L, Liu J, Jiang G, et al. S1P and cytokine production in microglia. Mol Neurobiol. 2016. ↩︎
Pchelina S, Tkachenko E, Emelianen K, et al. S1P in dopaminergic neurons. J Parkinsons Dis. 2014. ↩︎
Yao S, Miao C, Liang G, et al. S1P and mitochondrial function in PD models. Antioxid Redox Signal. 2014. ↩︎
Giusepponi F, Poli M, Colasanti M, et al. S1P and neuroinflammation in PD. Neuropharmacology. 2017. ↩︎
Schub M, Schwaninger M, Buttmann M, et al. S1P and peripheral immune cells. Neurology. 2015. ↩︎
Zunke F, Furuya N, Abeliovich M, et al. S1P and α-synuclein aggregation. Cell Mol Neurobiol. 2019. ↩︎
Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and S1P signaling. Cell Signal. 2014. ↩︎
Brinkmann V. 'FTY720: mechanism of action'. J Neurol. 2004. ↩︎
Foss FW, Snyder AH, Davis MD, et al. S1P1-selective agonists. Bioorg Med Chem Lett. 2007. ↩︎ ↩︎
Jaillard C, Harrison S, Stankoff B, et al. S1P and oligodendrocyte function. J Cell Biol. 2005. ↩︎
Miron VE, Hall JA, Kennedy TE, et al. S1P and remyelination in the CNS. Brain. 2008. ↩︎
Henríquez C, Torres K, Liao W, et al. S1P in ALS. J Mol Neurosci. 2019. ↩︎
Di Pardo A, Maglione V, Alvadia C, et al. S1P and glial function. Cell Mol Life Sci. 2017. ↩︎
Toman RE, Payne SG, Watterson KR, et al. S1P metabolism in HD. J Biol Chem. 2004. ↩︎
Gopez-Cruz A, Conrad T, Shao H, et al. S1P therapy in HD models. Mol Neurobiol. 2016. ↩︎
Hasegawa Y, Suzuki H, Soeda T, et al. S1P in ischemic stroke. Brain Res. 2010. ↩︎
Sims K, Ying L, Cai J, et al. S1P and cerebral ischemia. J Cereb Blood Flow Metab. 2008. ↩︎
Brinkmann V, Billich A, Baumruker T, et al. 'Fingolimod (FTY720): discovery and development'. Nat Rev Drug Discov. 2010. ↩︎
Chun J, Kihara A, Igarashi Y, et al. 'S1P receptor modulators: new drugs for multiple sclerosis'. Nat Rev Drug Discov. 2012. ↩︎
Pyne NJ, Bittman R, Pyne S. Sphingosine kinase inhibitors and cancer. Cell Calcium. 2011. ↩︎
Degagne E, Bittman R, Deguise J, et al. S1P lyase inhibitors. J Lipid Res. 2013. ↩︎
Roberts KG, Blazey C, Podos S. Second-generation S1P modulators. J Med Chem. 2014. ↩︎